{
    "name": "necitumumab",
    "comment": "Rx",
    "other_names": [
        "Portrazza"
    ],
    "classes": [
        "Antineoplastics",
        "EGFR Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/portrazza-necitumumab-1000041",
    "pregnancy": {
        "common": [
            "Based on animal data and its mechanism of action, can cause fetal harm when administered during pregnancy"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Advise females of reproductive potential to use effective contraception during treatment and for 3 months following the final dose"
                ]
            },
            {
                "type": "Animal studies",
                "description": [
                    "Disruption or depletion of EGFR in animal models results in impairment of embryo-fetal development, including effects on placental, lung, cardiac, skin, and neural development",
                    "The absence of EGFR signaling has resulted in embryolethality as well as postnatal death in animals"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Advise a nursing woman not to breastfeed during treatment and for 3 months following the final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Cardiopulmonary arrest and/or sudden death occurred in 3% of patients treated with necitumumab in combination with gemcitabine and cisplatin",
                "Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, with aggressive replacement when warranted during and after necitumumab (administer drug through dedicated IV line; do not mix with electrolyte or dextrose solutions) (see Administration)",
                "Hypomagnesemia occurred in 83% of patients receiving necitumumab in combination with gemcitabine and cisplatin, and was severe in 20% of patients",
                "Monitor patients for hypomagnesemia, hypocalcemia, and hypokalemia prior to each dose during treatment and for at least 8 weeks following completion",
                "Withhold drug for grade 3 or 4 electrolyte abnormalities",
                "Replete electrolytes as medically appropriate"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Cardiopulmonary arrest reported in 3% of patients with necitumumab plus gemcitabine and cisplatin compared with 0.6% with gemcitabine and cisplatin; closely monitor serum electrolytes during and after dose",
                "Monitor for hypomagnesemia (see Black Box Warnings)",
                "Discontinue if severe venous or arterial thrombosis occurs",
                "Dermatologic toxicities, including rash, dermatitis acneiform, acne, dry skin, pruritus, generalized rash, skin fissures, maculopapular rash and erythema, occurred in 79% of patients, typically within the first 2 weeks of therapy; limit sun exposure and discontinue for severe toxicity (see Dosage Modifications)",
                "Infusion-related reactions may occur; discontinue for severe reactions (see Dosage Modifications)",
                "Not indicated for nonsquamous NSCLC; increased toxicity and increased mortality occurred when necitumumab was added to pemetrexed and cisplatin therapy for these patients",
                "Based on animal data and its mechanism of action, can cause fetal harm when administered to a pregnant woman (see Pregnancy)"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Percentages listed below are for all grades of toxicity unless otherwise noted",
            "percent": "83"
        },
        {
            "name": "Hypomagnesemia",
            "percent": "45"
        },
        {
            "name": "Hypocalcemia",
            "percent": "44"
        },
        {
            "name": "Rash",
            "percent": "36"
        },
        {
            "name": "Hypocalcemia",
            "percent": "31"
        },
        {
            "name": "albumin corrected",
            "percent": "29"
        },
        {
            "name": "Hypophosphatemia",
            "percent": "28"
        },
        {
            "name": "Vomiting",
            "percent": "3-4"
        },
        {
            "name": "Hypokalemia",
            "percent": "20"
        },
        {
            "name": "Hypomagnesemia",
            "percent": "16"
        },
        {
            "name": "grade",
            "percent": "15"
        },
        {
            "name": "Diarrhea",
            "percent": "13"
        },
        {
            "name": "Dermatitis acneiform",
            "percent": "11"
        },
        {
            "name": "Weight decreased",
            "percent": "11"
        },
        {
            "name": "Stomatitis",
            "percent": "10"
        },
        {
            "name": "Headache",
            "percent": "9"
        },
        {
            "name": "Hemoptysis",
            "percent": "9"
        },
        {
            "name": "Venous thromboembolic events",
            "percent": "3-4"
        },
        {
            "name": "Acne",
            "percent": "8"
        },
        {
            "name": "Hypophosphatemia",
            "percent": "7"
        },
        {
            "name": "grade",
            "percent": "7"
        },
        {
            "name": "Paronychia",
            "percent": "7"
        },
        {
            "name": "Conjunctivitis",
            "percent": "7"
        },
        {
            "name": "Pruritus",
            "percent": "3-4"
        },
        {
            "name": "Dry skin",
            "percent": "6"
        },
        {
            "name": "Hypocalcemia",
            "percent": "3-4"
        },
        {
            "name": "grade",
            "percent": "5"
        },
        {
            "name": "Hypokalemia",
            "percent": "5"
        },
        {
            "name": "grade",
            "percent": "5"
        },
        {
            "name": "Skin fissures",
            "percent": "3-4"
        },
        {
            "name": "Pulmonary embolism",
            "percent": "5"
        },
        {
            "name": "Venous thromboembolic events",
            "percent": "3-4"
        },
        {
            "name": "grade",
            "percent": "4"
        },
        {
            "name": "Hypocalcemia",
            "percent": "3-4"
        },
        {
            "name": "albumin corrected",
            "percent": "3"
        },
        {
            "name": "grade",
            "percent": "3-4"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        },
        {
            "name": "grade",
            "percent": "3-4"
        },
        {
            "name": "Diarrhea",
            "percent": "1"
        },
        {
            "name": "grade",
            "percent": null
        },
        {
            "name": "Stomatitis",
            "percent": null
        },
        {
            "name": "grade",
            "percent": null
        }
    ]
}